Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 443 participants.
Also called NCT05731544
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 443 participants
- Sponsor
- Biomea Fusion Inc.
- Registry
-
NCT05731544
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT05731544. Randomized; double masking; primary purpose treatment. Start 2022-08-17 (actual); primary completion 2024-11-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- BMF-219
- Intervention (Drug)
- Placebo
- Lead sponsor
- Biomea Fusion Inc.
Record details
- Record id
cardio:ct-nct05731544- Content hash
df14d7f4cc67d7edb56491916ab7421b65057cfc5b9643c0da1dc593d3a5326b